These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 3454800)

  • 1. In vitro produced human antibodies in the treatment of superficial bladder cancer.
    Corrado F; Pizza G; Casanova S; De Vinci C; Fini M; Severini G; Menniti D; Corrado G
    J Exp Pathol; 1987; 3(4):347-58. PubMed ID: 3454800
    [No Abstract]   [Full Text] [Related]  

  • 2. Antibody drug carrier for immunotherapy of superficial bladder cancer: ultrastructural studies.
    de Harven E; Fradet Y; Connolly JG; Hanna W; He S; Wang Y; Choi BC; McGroarty R; Bootsma G; Tilups A
    Cancer Res; 1992 Jun; 52(11):3131-7. PubMed ID: 1591726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-2 in the treatment of infiltrating bladder cancer.
    Pizza G; Berton F; Casanova S; De Vinci C; Corrado F
    J Exp Pathol; 1987; 3(4):525-31. PubMed ID: 3502649
    [No Abstract]   [Full Text] [Related]  

  • 4. Immunotherapy of bladder cancer using autologous dendritic cells pulsed with human lymphocyte antigen-A24-specific MAGE-3 peptide.
    Nishiyama T; Tachibana M; Horiguchi Y; Nakamura K; Ikeda Y; Takesako K; Murai M
    Clin Cancer Res; 2001 Jan; 7(1):23-31. PubMed ID: 11205913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro production of human antibodies against bladder cancer: characterization and diagnostic implications.
    Pizza G; De Vinci C
    J Exp Pathol; 1987; 3(4):335-46. PubMed ID: 2457663
    [No Abstract]   [Full Text] [Related]  

  • 6. High grade superficial (G3t1) transitional cell carcinoma of the bladder treated with intravesical Bacillus Calmette-Guerin (BCG).
    Pansadoro V; Emiliozzi P; depaula F; Scarpone P; Pizzo M; Federico G; Martini M; Pansadoro A; Sternberg CN
    J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):223-7. PubMed ID: 16767936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapy of superficial bladder cancer.
    Nseyo UO; Lamm DL
    Semin Oncol; 1996 Oct; 23(5):598-604. PubMed ID: 8893870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-risk superficial bladder cancer: intravesical therapy for T1 G3 transitional cell carcinoma of the urinary bladder.
    Pham HT; Soloway MS
    Semin Urol Oncol; 1997 Aug; 15(3):147-53. PubMed ID: 9394909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin.
    Thalmann GN; Sermier A; Rentsch C; Möhrle K; Cecchini MG; Studer UE
    J Urol; 2000 Dec; 164(6):2129-33. PubMed ID: 11061941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
    Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
    Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer.
    Librenjak D; Situm M; Eterovic D; Dogas Z; Gotovac J
    Croat Med J; 2003 Apr; 44(2):187-92. PubMed ID: 12698510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravesical immunotoxin as adjuvant therapy to prevent the recurrence of bladder cancer.
    Zang Z; Xu H; Yu L; Yang D; Xie S; Shi Y; Li Z; Li J; Wang J; Li M; Guo Y; Gu F
    Chin Med J (Engl); 2000 Nov; 113(11):1002-6. PubMed ID: 11776112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravesical bacillus Calmette-Guérin therapy for T1 superficial bladder cancer.
    Demkow T; Alter A; Wiechno P
    Urol Int; 2008; 80(1):74-9. PubMed ID: 18204238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Intravesical instillation in the treatment of superficial tumors of the bladder].
    Chopin DK
    Prog Urol; 1998 Apr; 8(2):268-73. PubMed ID: 9615941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Trials of immunotherapy in tumors of the urinary tract].
    Corrado F; Pizza G
    Arch Esp Urol; 1984 Dec; 37 Suppl 2():659-66. PubMed ID: 6336141
    [No Abstract]   [Full Text] [Related]  

  • 16. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
    Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
    J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of superficial transitional cell carcinoma of the bladder.
    Fleischmann J; Goldberg G
    Semin Urol; 1993 Nov; 11(4):193-204. PubMed ID: 8290825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cytokine therapy of superficial bladder carcinoma. Mechanisms of action and results of therapy].
    Otto T; Kälble T
    Urologe A; 1994 Nov; 33(6):540-6. PubMed ID: 7817454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Polyarthritis as a rare complication in BCG immunoprophylaxis of urinary bladder cancer].
    Varentsov GI; Zakhmatov IuM; Kornev AI; Otvetchikov IN
    Urologiia; 1999; (5):29-30. PubMed ID: 11150151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Difficult decisions in urologic oncology: management of high-grade T1 transitional cell carcinoma of the bladder.
    Soloway MS; Lee CT; Steinberg GD; Ghandi AA; Jewett MA
    Urol Oncol; 2007; 25(4):338-40. PubMed ID: 17628304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.